SGLT2 inhibitors raise haemoglobin by about 0.6 g/dL

Design

Systematic review and meta-analysis of double-blind randomised trials

Population

85 trials, 70,543 adults with diabetes, heart failure, kidney or cardiovascular disease

Primary outcome

Change in haemoglobin and haematocrit

Effect

Haemoglobin +0.60 g/dL (0.55–0.66); haematocrit +2.36% (2.19–2.52)

A meta-analysis pooled 85 double-blind randomised trials with 70,543 participants with diabetes, heart failure, kidney disease or cardiovascular disease, followed for a median of 24 weeks.

Against control, SGLT2 inhibitors raised haemoglobin by 0.60 g/dL (95% CI 0.55–0.66) and haematocrit by 2.36 percentage points (2.19–2.52). Erythropoietin rose slightly and transferrin saturation fell slightly, consistent with stimulated red cell production rather than simple haemoconcentration alone.

The authors call the clinical significance unclear, and it is. The practical point is interpretive: for the millions now taking these drugs, a modest rise in haemoglobin is expected. It should not prompt a polycythaemia work-up by itself, and a normal value on treatment may mask anaemia that was there before.

• Expect haemoglobin to rise by about 0.5 to 0.7 g/dL after starting an SGLT2 inhibitor.
• Record a baseline full blood count before starting where practical.
• Do not investigate a modest isolated rise in haematocrit as polycythaemia without considering the drug.
• Check iron studies when anaemia is suspected, since a near-normal haemoglobin may be falsely reassuring.
• Do not stop an indicated SGLT2 inhibitor because of the expected haemoglobin rise.

Why it matters

A predictable lab effect of a widely used drug class can trigger needless referrals or hide real anaemia.

Don't overread it

The study measured laboratory values, not whether the haemoglobin rise contributes to the drugs' cardiorenal benefits.

The statistics, in plain English

The 0.60 g/dL difference is very precise across 85 trials, so the effect is real. Statistical precision is not clinical importance, though, and the trials did not test whether it changes outcomes.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.